Most Read Articles
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
3 days ago
OZEMPIC – Semaglutide 1.34 mg/mL soln for inj
Audrey Abella, 11 Sep 2020
A prasugrel de-escalation strategy significantly reduced the risk of NACE* and bleeding events in patients with ACS** after PCI*** compared with the conventional strategy, results of the HOST-REDUCE-POLYTECH-ACS# trial have shown.

NSAIDs heighten risk for cardiovascular, bleeding risks after MI

07 Aug 2020

Concomitant treatment with a nonsteroidal anti-inflammatory drug (NSAID) following myocardial infarction (MI) is associated with a higher risk of cardiovascular and bleeding events, a study has shown.

The authors investigated the risk for cardiovascular and bleeding events according to groups of antithrombotic medications and subtypes of NSAIDs. They accessed the Health Insurance Review and Assessment Service database between 2009 and 2013 and enrolled 108,232 patients (mean age, 64.2 years; 72.1 percent men) with first diagnosed MI in this nationwide cohort study.

Patients were then divided into groups based on their prescribed antithrombotic medications. Thromboembolic cardiovascular and clinically relevant bleeding events were the study outcomes. The risk for adverse clinical events were evaluated by ongoing NSAID treatment and subtypes of NSAIDs.

Over a mean follow-up of 2.3 years, concomitant NSAID treatment significantly elevated the risk for cardiovascular events (hazard ratio [HR], 6.96, 95 percent confidence interval [CI], 6.24–6.77; p<0.001) and bleeding events (HR, 4.08, 95 percent CI, 3.51–4.73; p<0.001) compared with no NSAID treatment.

Among NSAID subtypes, celecoxib and meloxicam showed the lowest risk for cardiovascular (celecoxib: HR, 4.65, 95 percent CI, 3.17–6.82; p<0.001 meloxicam: HR, 3.03, 95 percent CI, 1.68–5.47; p<0.001) and bleeding events (celecoxib: HR, 3.44, 95 percent CI, 2.20–5.39; p<0.001; meloxicam: HR, 2.80, 95 percent CI, 1.40–5.60; p<0.001).

“Although NSAID treatment should be avoided after MI, celecoxib and meloxicam could be considered as alternative options in cases in which NSAID use is unavoidable,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
3 days ago
OZEMPIC – Semaglutide 1.34 mg/mL soln for inj
Audrey Abella, 11 Sep 2020
A prasugrel de-escalation strategy significantly reduced the risk of NACE* and bleeding events in patients with ACS** after PCI*** compared with the conventional strategy, results of the HOST-REDUCE-POLYTECH-ACS# trial have shown.